Better Therapeutics, Inc. · OTC:BTTX
Better Therapeutics — Corporate Update (July 2023)
38 slides from Better Therapeutics's corporate update, Jul 12, 2023
Slide 1: FDA Grants Authorization for AspyreRx (Formerly BT-001)
Exhibit 99.2 | on FDA Grants Authorization for AspyreRx™ (Formerly BT-009 JULY 11, 2023 Better THERAPEUTICS
Slide 2: Introduction
Better’ Introduction THERAPEUTICS Mark Heinen Chief Financial Officer
Slide 3: Better Therapeutics Team
Better Therapeutics Team Frank Karbe Mark Heinen Mark Berman, MD Diane Gomez- Thinnes Kristin Wynholds President & Chief Financial Officer Chief Medical Officer Chief Commercial Officer Chief Product Officer Chief Executive Officer Better 3
Slide 4: Disclaimer
Disclaimer This Gl tion”) is for it i purposes only. The information contained herein does not purport to be all-inclusive and neither Better Therapeutics, Inc. (“BetterTX” or the "Company’) nor any of its respective affiliates nor any of its or their control persons, officers, directors, employees
Slide 5: Opening Remarks
~ Opening Remarks THERAPEUTICS Frank Karbe js President & Chief Executive Officer
Slide 6: AspyreRx Now FDA Authorized in the U.S. for the Treatment of Type 2 Diabetes
AspyreRx™ Now FDA Authorized in the U.S. for the Treatment of Type 2 Diabetes (T2D) HT ‘deas 5 =a H bo HI © change ae ability AspyreRx (formerly BT-001) is the first behavioral therapy Class 2 device for treatment of a cardiometabolic disease ¢ A prescription-only digital therapeutic treatment to pr
Slide 7: AspyreRx is differentiated from health and wellness apps in meaningful ways
AspyreRx is differentiated from health and wellness apps in meaningful ways Health & Wellness AspyreRx Applications Clinically Validated via a Randomized Controlled Trial FDA Authorized as a Class 2 Medical Device Treatment Claim Prescribed by a Healthcare Provider Adheres to Strict Security and Dat
Slide 8: Type 2 Diabetes is a health crisis in the United States
Type 2Diabetes is a health crisis in the United States Adults in the US have uncontrolled T2D' despite being on standard of care medications" Adults in the US have Type 2 Diabetes ™ of adults in the US have prediabetes' in annual Rx drug spending alone’ Better® — souces: 1 centers for Disease Contro
Slide 9: Diabetes is the most expensive chronic condition in the US
Diabetes is the most expensive chronic condition in the US and prevalence continues to rapidly increase’? — Total US Healthcare Expenditures ($ in trillions) HB Americans Diagnosed with Diabetes (millions) 40 Al Prevalence ve % 30 projected to increase (0) 2 of total US healthcare $ expenditure attr
Slide 10: FDA Authorization is a Significant Milestone
FDA Authorization is a Significant Milestone Better AspyreRx empowers patients to make & sustain behavior changes that are the cornerstone of diabetes management Facilitates implementation of T2D treatment guidelines, lowers patient access hurdles Newly established device classification provides fou
Slide 11: Review of Clinical Data
. Review of Clinical Data THERAPEUTICS Mark Berman, MD Chief Medical Officer
Slide 12: Overview of US Prescribing Information for AspyreRx
Overview of US Prescribing Information for AspyreRx Indication for Use Statement ae Progress BT-001is a prescription- only digital therapeutic device intended to provide cognitive behavioral therapy to patients 18 years or older with type 2 diabetes. The device targets behavior to aid in the managem
Slide 13: Overview of US Prescribing Information for AspyreRx
Overview of US Prescribing Information for AspyreRx Usage Statement ¢ Compared to standard of care treatment alone, consistent use for 90 days has been shown, on average, to result in more improvements in glycemic control, fewer diabetes-related risks to the patient, and more durable results, with b
Slide 14: BT-001 pivotal study was a randomized, controlled, open-label clinical trial
The BT-001 pivotal study was a randomized, controlled, open-label clinical trial designed to evaluate safety and effectiveness after two 90-day treatments for T2D BT-001+ Standard of Care ; ; : N=325 Primary Endpoint Secondary Endpoint Patients with S (Day 90) (Day #80) atients wi 2 Uncontrolled E B
Slide 15: Broad eligibility criteria and decentralized recruitment ensured a diverse population
Broad eligibility criteria and decentralized recruitment were used to ensure a nationally representative, diverse population derived from 6 US states Better® Baseline characteristics included a robust representation of different races and ethnicities, as well diversity in socioeconomic status and le
Slide 16: Pivotal study designed to test BT-001 in a real-world, difficult-to-treat population
The BT-001 Pivotal Study was designed to test BT-001in a real-world, difficult-to-treat population The trial set a high bar to demonstrate efficacy by increasing the likelihood the Control group would receive more medications No Glycemic Equipoise Key attributes allowing for imbalance of medication
Slide 17: BT-001 reduced A1c despite added medication in the control group
BT-001reduced A‘c despite on-study addition of more diabetes medication in the Standard of Care control group Better’ % Mean Change in Atc Baseline A1c 0.2 D90 Atc D180 Atc -0.1 -0.2 -0.3 -0.4 Primary Endpoint 04% Delta, p <0.0001 Intent-to-Treat Analysis Secondary Endpoint 0.3% Delta, p=0.01 SOC BT
Slide 18: Patients who used BT-001 more had greater reduction in A1c
Patients who used BT-001more had greater reduction in A1c Higher dose of CBT lessons completed associated with larger A‘c improvements at #80 days Low Use of Behavior Moderate Use of High Use of Therapy Behavior Therapy Behavior Therapy < 1 lessons 10-20 lessons >20 lessons t') 8 =z 0.1 & S -0.2 i G
Slide 19: Meaningful Responders saw a mean decrease of 1.3% HbA1c over 180 days
BT-001Meaningful Responders saw a mean decrease of - 1.3% HbA‘C over 180 days "Meaningful Responders” defined as 0.4% or more A‘c improvement and accounted for 50.4% of the BT-001 group MEAN -13% MEDIAN ha =1.1% % of BT-001 patients =~ fo) for) Sj PS aS s BS | a -04 -05 -06 -07 -08 -09 -1 -11 -12 -1
Slide 20: Fewer total adverse events and serious AEs in BT-001 patients
Statistically significant fewer total adverse events (AEs) and serious AEs occurred in BT-001 patients! Summary of AEs at 180 Days nee ae Any treatment-emergent AE, n (%) B5 (415) 88 (64.8) P<0.001 Treatment-emergent AE possibly/probably related to study intervention, n (%) 3 (0.9) 0 (0) Serious tre
Slide 21: Commercial Update
. Commercial Update museaveuucs Diane Gomez- Thinnes Chief Commercial Officer
Slide 22: AspyreRx
AspyreRx Daily Plan © Plant-Based Meals sting Blood Sugar Better”
Slide 23: Only AspyreRx delivers CBT to treat patients with T2D
Only AspyreRx delivers CBT to treat patients with T2D by targeting the underlying behaviors that contribute to disease progression in a proven, convenient, engaging digital app MECHANISM OF ACTION Reinforce Think 4 . Cognitive Behavioral Therapy Leam, e Vy Source: BT-001 Clinical Trial ? Meaningful
Slide 24: Initial target population includes uncontrolled patients across the disease continuum
Initial target population includes uncontrolled patients across the disease continuum Type 2 Diabetes Typical Disease Progression Most motivated Most motivated Insulin Advanced Treatment Comorbidities wv Newly Diagnosed or Change / Escalation in Treatment Initial focus will be the uncontrolled popul
Slide 25: Initial Targeted Approach to Commercial Launch
Initial Targeted Approach to Commercial Launch ¢ Custom teams for unique geographical needs ¢ Virtual resources for flexibility ¢ Will execute on this strategy with ~50 FTEs Better Claims Count 2,260 Better’ FOCUS ON COVERAGE Payers FOCUS ON PRESCRIBER DEMAND LS aT Health Systems Bm Targeted Physici
Slide 26: Successful commercialization requires educating all stakeholders
Successful commercialization requires that we educate all stakeholders on the benefits of this new digital treatment option r? PROVIDERS Position AspyreRx as effective and convenient foundation of treatment Ge ald PATIENTS Deliver positive experience, ensuring high engagement and treatment success w
Slide 27: Committed to a positive experience for providers and patients
Committed to a positive experience for both health care providers and patients PROVIDERS HCP toolkit and patient selection guidance Prescribing, coverage and pre- authorization support Support for patients to easily access therapy and engage in treatment Better” PATIENTS Prescription and coverage su
Slide 28: Strategy to target regionally dominant payers
As awareness of PDTs grows, we are making progress with our strategy to target regionally dominant payers Connected with 65% of Top 20 Regional Payers >4. Engagements with Payers, PBMs, Payer / Providers’ Better” “Includes market research, consultant engagements, PIE meetings, informal meetings Paye
Slide 29: Early pricing research suggests $500-$800 net per 90-day prescription
Early pricing research suggests price range $500-$800 net for one 90-day prescription Pricing research conducted prior to final pivotal trial results— new pricing study currently underway Likelihood of Providing Coverage (1to 7 scale) 1 (notatalllikely) m2 m3 m4 m5 "6 &7 (highly likely) TEST PRICE $
Slide 30: Focused Commercial Strategy to Gain Early Traction
Focused Commercial Strategy to Gain Early Traction Better” Targeting Top 20 Regionally Dominant Payers Phasing launch into 5-6 initial geographies Anticipating market release in Q4 Payer contract negotiations begin immediately Launch metrics shared during Q2 Earnings Call
Slide 31: Closing Comments
» Closing Comments THERAPEUTICS Frank Karbe >. President & Chief Executive Officer
Slide 32: Progress towards resolving our key risks
Progress towards resolving our 3 key risks @ Regulatory |/ @ Commercial / Launch Execution 3 Financing Better”
Slide 33: AspyreRx has substantial potential in T2D alone
AspyreRx has substantial potential in T2D alone ASSUMPTIONS AT PEAK Total US Adult % T2D Population Prevalence * Uncontrolled Only uncontrolled population included in our model Total Addressable Market ~50% of diagnosed T2D patients addressable per label x % Lives Covered ~75% Coverage % rere Penetr
Slide 34: Substantial potential achievable with only 5% utilization
Substantial potential achievable with only 5% utilization AspyreRx Peak Utilization in US ¢ Projected peak revenue achievable with Patients Diagnosed with T2D 5% share of all patients diagnosed with T2D or 11% share of uncontrolled T2D >$2 Billion patients Net Revenue’ 5% * Additional revenue upside
Slide 35: Future Indications
FUTURE INDICATIONS. With moderate platform modifications, we Can pursue a broad range of potential indications that may offer significant upside $ figures in select bubbles represent annual direct US healthcare expenditures Better” a aN Obesity = 2 ( Post-Mh | — 8 CKD 2 \ 7 (Stage +3 | 8 \ $878 / 5
Slide 36: Financing Strategy
Financing Strategy Better” ¢ Disciplined management of dilution ¢ Address majority of financing overhang through non- share dilutive options * Optimistic in ability to meet critical milestones ¢ Highly cost-efficient operating model 36
Slide 37: We envision AspyreRx becoming part of the standard of care for adults with T2D
We envision AspyreRx becoming part of the standard of care for adults with T2D Better” Significant & growing unmet medical need In-line with existing treatment guidelines Valuable at any stage in T2D disease progression Broadly accessible to anyone with a smartphone Potential cost savings for payers
Slide 38: Questions & Answers
Questions & Answers Frank Karbe Mark Heinen Mark Berman, MD Diane Gomez-Thinnes Kristin Wynholds President & Chief Financial Officer Chief Medical Officer Chief Commercial Officer Chief Product Officer Chief Executive Officer Better